Drug Profile
Rivipansel subcutaneous - Pfizer
Alternative Names: PF-06460031/PF-06744547; PF-06460031/rHuPH20; Rivipansel/PF-06744547; Rivipansel/rHuPH20Latest Information Update: 10 Nov 2016
Price :
$50
*
At a glance
- Originator GlycoMimetics
- Developer Pfizer
- Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
- Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors; PCSK9 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Vaso-occlusive crisis
Most Recent Events
- 07 Nov 2016 Discontinued - Phase-I for Vaso-occlusive crisis related to sickle cell anaemia (In volunteers) in Belgium (SC)
- 01 Apr 2016 Pfizer completes a phase I trial in Healthy volunteers in Belgium (SC) (NCT02217917)
- 01 Oct 2015 Phase-I clinical trials in Vaso-occlusive crisis related to sickle cell anaemia (In volunteers) in Belgium (SC)